Thursday, Oct 23, 2025 · SEC filings
What the smart money revealed on Oct 23
155 insider filings came in. We hid 34 planned (10b5-1) sellers and 78 people whose filings were routine, like grants and tax withholding.
Summit Therapeutics (SMMT) Director Yu Xia bought $10M
533,617 shares on the open market. Not a grant or an option exercise.
Summit Therapeutics (SMMT) Co-CEO Robert Duggan bought $500K
26,680 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 6 checked quarters beat the typical stock 6 months later.
Turn Therapeutics (TTRX) Director Arthur Golden bought $100K
20,202 shares on the open market. Not a grant or an option exercise.
HEICO (HEI) Director Mark Hildebrandt bought $99.5K
400 shares on the open market. Not a grant or an option exercise.
Oracle (ORCL) CEO Clayton Magouyrk sold $11.1M
Not marked as a planned 10b5-1 sale. Sold 21% of the shares they held directly. Still holds 154,030 shares.
Oracle (ORCL) EVP Maria Smith sold $2.8M
Not marked as a planned 10b5-1 sale. Sold 18% of the shares they held directly. Still holds 47,083 shares.
Delta Air Lines (DAL) EVP & Chief of Operations John Laughter sold $1.45M
Not marked as a planned 10b5-1 sale. Sold 22% of the shares they held directly. Still holds 81,109 shares.
Show 9 more real buys
Show 5 more real sales
13F season
Holdings as of Sep 30, 2025 are due Nov 14
81 funds have filed so far. 74 filed for the quarter before.
Biggest real insider buys, Oct 17–23
Open-market buys by officers and directors, filed in the 7 days up to Oct 23.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.